Concourse Financial Group Securities, Inc. Finch Therapeutics Group, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$0.34 - $0.56 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$0.36 - $56.4 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$1.75 - $51.3 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$1.91 - $5.11 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$5.02 - $10.47 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$8.95 - $16.88 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$12.2 - $16.75 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$12.03 - $17.51 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$15.54 - $21.32 $0 - $0
0 New
0 $0

About Finch Therapeutics Group, Inc.

FNCH Quotes by TradingView
  • Ticker FNCH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,688,400
  • Market Cap $546M
  • Description
  • Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...
More about FNCH
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email